- Metformin is associated with improved endothelial function in patients with polycystic ovary syndrome (PCOS), according to a small trial.
Why this matters
- PCOS has been linked to increased risk for cardiometabolic syndrome.
- Metformin was associated with improved endothelial function in patients with abnormal baseline endothelial function (P<.001>
- Metformin was not associated with altered endothelial function in patients with normal baseline endothelial function (P=.11).
- Baseline endothelial dysfunction was a significant predictor of change in endothelial function in analysis adjusted for homeostasis model assessment of insulin resistance (P=.002).
- 42 women with PCOS were randomly assigned to 1500 mg/day of metformin (N=29) or no treatment (N=13) for 3 months.
- Funding: St. Jude Medical Foundation; NIH; National Center for Advancing Translational Sciences.
- Small patient sample size.
- No long-term follow-up.
- No placebo-controlled group.